Key result
Apparent treatment-resistant hypertension linked to ~2.5-fold higher rate of incident MI, stroke, or HF.
Why the study?
Apparent treatment-resistant hypertension (aTRH) is associated with adverse cardiovascular and kidney outcomes, but contemporary real-world estimates that account for time at risk and distinguish incident from pre-existing disease remain limited.
Does apparent treatment-resistant hypertension increase the risk of incident myocardial infarction, stroke, or heart failure compared to non-resistant blood pressure phenotypes in adult outpatients?
Cohort (n=83,156)
No
Does apparent treatment-resistant hypertension increase the risk of incident myocardial infarction, stroke, or heart failure compared to non-resistant blood pressure phenotypes in adult outpatients?
Answers are grounded in this paper and cite their sources.
In a large routine outpatient cohort, apparent treatment-resistant hypertension affected nearly 9% of adults, was largely persistent, and independently conferred more than a two-fold increased risk of incident cardiovascular and kidney events and a 78% higher risk of death.
Apparent treatment-resistant hypertension (aTRH) is associated with adverse cardiovascular and kidney outcomes, but contemporary real-world estimates that account for time at risk and distinguish incident from pre-existing disease remain limited. We performed a retrospective cohort study of 83,156 adults receiving outpatient care at Naples Comprehensive Health between April 2022 and April 2024. Baseline blood pressure (BP) phenotype was determined from the first recorded office BP and the antihypertensive medication list, with goals individualised by cardiovascular disease (CVD) history (< 130/80 mm Hg with CVD; <140/90 mm Hg without CVD). Patients were classified as having normal BP, controlled BP on therapy, uncontrolled hypertension not meeting resistance criteria (non-TRH), or aTRH. The primary outcome was a composite of incident myocardial infarction, stroke, or heart failure. For every outcome, patients with that condition recorded at baseline were excluded from the denominator. Associations were estimated with multivariable Poisson models incorporating a person-time offset, yielding incidence rate ratios (IRRs); all-cause mortality was analysed with Cox proportional hazards regression. Among 83,156 adults, 7,299 (8.8%) met criteria for aTRH, of whom 5,362 (73.5%) were above goal on three or more agents and 1,937 (26.5%) were at goal on four or more. Over 130,618 person-years (mean follow-up 18.8 months), the incidence of the primary composite outcome rose stepwise across phenotypes, from 25.6 per 1,000 person-years with normal BP to 132.7 with aTRH. After adjustment for age, sex, race, diabetes, prior CVD, smoking, obesity, chronic kidney disease, dyslipidaemia and malignancy, aTRH was associated with the primary composite outcome (IRR 2.46; 95% CI, 2.26–2.68), heart failure (3.31; 2.96–3.69), acute kidney injury (2.86; 2.53–3.24), chronic kidney disease (2.45; 2.23–2.69), end-stage kidney disease (4.46; 2.50–7.96) and all-cause mortality (hazard ratio 1.78; 1.41–2.26). aTRH was persistent: 68.4% remained in the aTRH category at follow-up, whereas 22.7% transitioned to controlled BP. Findings were unchanged across four alternative phenotype definitions. In routine outpatient care, aTRH affected approximately one in eleven adults, was largely persistent over a mean of 18.8 months, and was independently associated with incident cardiovascular and kidney disease and with death. The gradient was steepest for heart failure and kidney outcomes, supporting earlier recognition and systematic treatment optimisation.
No takes yet. Share an insight, caveat, or question.
Mamprejew et al. (2026) conducted a cohort in Apparent treatment-resistant hypertension (aTRH) (n=83,156). Apparent treatment-resistant hypertension (aTRH) vs. Normal blood pressure, controlled blood pressure on therapy, or uncontrolled non-resistant hypertension was evaluated on Composite of incident myocardial infarction, stroke, or heart failure (IRR 2.46, 95% CI 2.26-2.68). Apparent treatment-resistant hypertension was independently associated with a higher rate of incident myocardial infarction, stroke, or heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: